Argos Therapeutics Inc. | Income Statement
Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
Sales/Revenue
4,421.70
1,974.00
518.30
945.50
1,899.40
SG&A Expense
28,042.00
53,532.20
72,385.40
51,558.20
32,871.40
EBIT
24,231.80
52,124.30
-
51,565.10
31,939.90
Unusual Expense
355.40
200.00
-
266.20
10,171.30
Non Operating Income/Expense
47.60
75.30
2.80
11.90
2,777.40
Interest Expense
4.70
1,123.60
2,263.60
1,774.70
1,308.20
Pretax Income
23,921.60
53,305.90
74,788.50
53,028.10
40,577.50
Consolidated Net Income
23,921.60
53,305.90
74,788.50
53,028.10
40,577.50
Net Income
23,921.60
53,305.90
74,788.50
53,028.10
40,577.50
Net Income After Extraordinaries
23,921.60
53,305.90
74,788.50
53,028.10
40,577.50
Net Income Available to Common
33,874.70
54,169.20
74,788.50
53,028.10
40,577.50
EPS (Basic)
491.23
62.40
73.20
33.20
13.45
Basic Shares Outstanding
69.00
868.40
1,022.90
1,600.30
3,017.40
EPS (Diluted)
491.23
62.38
73.12
33.14
13.45
Diluted Shares Outstanding
69.00
868.40
1,022.90
1,600.30
3,017.40
EBITDA
23,620.40
51,558.10
71,867.10
50,612.70
30,972.00
Non-Operating Interest Income
7.20
66.60
25.40
57.30
64.50
Preferred Dividends
9,953.10
863.20
-
-
-
About Argos Therapeutics
View Profile
